Bayer AG Revenue in 2025

Bayer AG reported $49.5B in revenue for fiscal year 2025. This represents a decline of 2.6% compared to the 2024 figure of $50.8B.

Revenue of $50.8 billion in FY2024 is essentially flat compared to $51.9 billion in 2023 and $50.7 billion in 2022, with FY2025 dropping slightly to approximately $49.5 billion. Net loss of -$2.55 billion in FY2024 reflects impairment charges, Roundup litigation provisions, and the restructuring costs of the Dynamic Shared Ownership program — not a collapse in underlying operating performance, but not profitable either. The Pharmaceutical segment's growth products — Nubeqa and Kerendia — are accelerating. Nubeqa for non-metastatic castration-resistant prostate cancer has been gaining market share from competitors. Kerendia for chronic kidney disease in Type 2 diabetes patients addresses a large population with limited treatment options. Both are on trajectories that suggest they can become multi-billion dollar franchises, which matters because Xarelto generates roughly $6 billion globally and its US exclusivity is finite. The Monsanto acquisition is carried at its purchase price minus accumulated amortization and impairments. The actual financial liability — how much Bayer will ultimately pay to resolve Roundup litigation — cannot be precisely estimated because the legal proceedings are ongoing and juries continue to award substantial damages. The company has set aside billions in provisions, but analysts who model Bayer's valuation must make assumptions about total settlement costs that carry enormous uncertainty. The Dynamic Shared Ownership restructuring reduced costs but generated $705 million in corn seed impairment reversals and similar agricultural reversals in 2025 — accounting outcomes that improve reported earnings without representing genuine business improvement. The $0.12 minimum dividend signals that cash generation is being directed entirely toward debt reduction rather than shareholder returns, a posture that will remain until the Roundup liability is substantially resolved.